Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multiple-dose study of IPH1101 with or without low-dose IL-2 in treatment-naive hepatitis C
2007-002139-94Phase 2Active
- Sponsor
- Innate Pharma
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of IPH1101 in hepatitis C virus infection (2 arms), sponsored by Innate Pharma. Primary endpoint: Change in HCV viral load. Started Apr 2007; status: active.
02
Drugs
IPH1101
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2007-002139-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002139-94.